Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Researchers isolated the fragment because it appeared to carry the repair signaling activity of the larger molecule in a more stable form
Updated July 2026
Suitable Candidates Suitable candidates for peptide therapy include anyone interested in enhancing their overall health and wellness
Vaginal and Endometrial Atrophy Declining estrogen levels cause the vaginal and uterine tissues to thin, dry out, and become fragile
The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
US$ 20.89
US$ 22.20
US$ 29.83
US$ 28.89
